Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
40%(2 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_1
2
20%
Ph not_applicable
3
30%
Ph phase_3
3
30%
Ph phase_4
2
20%

Phase Distribution

2

Early Stage

0

Mid Stage

5

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 3Large-scale testing
3(30.0%)
Phase 4Post-market surveillance
2(20.0%)
N/ANon-phased studies
3(30.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Active(1)
Completed(5)
Terminated(1)
Other(3)

Detailed Status

Completed5
unknown3
Not yet recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 33 (30.0%)
Phase 42 (20.0%)
N/A3 (30.0%)

Trials by Status

unknown330%
not_yet_recruiting110%
completed550%
terminated110%

Recent Activity

Clinical Trials (10)

Drug Details

Intervention Type
DRUG
Total Trials
10